Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBEREM: Remifentanil Dosing for Intubation
NCT05026125Phase 4Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jan 2022
- Primary completion
- Aug 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of remifentanil in obesity, sponsored by Centre hospitalier universitaire de Toulouse. Started Jan 2022; status: completed.
02
Drugs
remifentanil
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05026125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05026125.